Novomix 50 Flexpen (Insulin Aspart)

Insulin aspart, the active ingredient in Novomix 50 Flexpen, is a rapid‑acting insulin analog presented as a pen‑sub‑injector for subcutaneous use. It treats diabetes mellitus by providing mealtime glucose control in adults and children. GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novomix 50 Flexpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novomix 50 Flexpen is a rapid‑acting insulin analog used in the management of blood glucose levels in diabetes mellitus. It is indicated for: - Type 1 diabetes mellitus: improves post‑prandial glucose control. - Type 2 diabetes mellitus: provides mealtime insulin coverage when oral agents are insufficient. - Gestational diabetes mellitus: assists in controlling post‑meal glucose excursions under specialist supervision. - Pediatric diabetes (age ≥ 2 years): offers rapid insulin action for meal‑time dosing. - Hospitalised patients requiring insulin infusion transition to subcutaneous therapy: facilitates smooth glucose management during discharge. - Patients using insulin pump therapy as a bolus insulin supplement: serves as a rapid‑acting bolus option.

Novomix 50 Flexpen may cause a range of adverse reactions, most of which are related to its pharmacologic action or formulation.

Common Side Effects: - Hypoglycaemia: low blood glucose levels, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized fat tissue changes with repeated injections. - Weight gain: modest increase associated with improved glycaemic control. - Edema: mild peripheral swelling, often transient.

Serious or Rare Side Effects: - Severe hypoglycaemic episodes requiring assistance. - Allergic reactions: urticaria, angio‑edema, or anaphylaxis. - Persistent hyperglycaemia despite dosing adjustments. - Unexplained visual disturbances. - Acute metabolic acidosis, including ketoacidosis. - Injection‑site infection. - Rare cases of insulin antibody formation.

Novomix 50 Flexpen should be used with careful clinical monitoring and patient education.

- Dose titration: adjust based on self‑monitored blood glucose and meal patterns. - Hypoglycaemia risk: educate patients on recognizing and treating low blood glucose. - Concomitant medications: review for agents that may potentiate or mask hypoglycaemia. - Pregnancy and lactation: use only if benefits outweigh risks and under specialist care. - Renal or hepatic impairment: monitor closely and consider dose modifications. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Novomix 50 Flexpen can interact with several drug classes, altering glucose control or increasing adverse event risk.

Major Interactions (Avoid): - Beta‑beta‑beta β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β β beta beta beta beta beta beta ...

Moderate  i  t  t

t

t \